TOS	Procedure Code	Code Description	Fee	Effective Date of Service*	End Date of Service
03	U0002	COVID-19 Lab Test Non-CDC	\$51.33	02/04/2020	04/19/2020
03	86328	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$45.23	04/10/2020	TBD
03	86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$42.13	04/10/2020	TBD
03	87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	\$51.33	03/13/2020*	TBD
03	U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.	\$75.00	01/01/2021	TBD
03	U0004	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.	\$75.00	01/01/2021	TBD
03	U0005	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either HCPCS code U0003 or U0004) SARS-CoV-2 CMS-2020-01-R2	\$25.00	01/01/2021	TBD
03	87426	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g. SARS-CoV, SARSCOV-2 (COVID-19])	\$45.23	06/25/2020*	TBD
03	87428	Infectious agent antigen detection by immunoassay technique, (eg., enzyme immunoassay [EIA], enzyme-linked immunosorberit assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg. SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B	\$73.49	11/10/2020	TBD
03	0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$416.78	06/25/2020*	TBD
03	0224U	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed	\$42.13	06/25/2020*	TBD
03	0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$416.78	05/20/2020*	TBD
03	86408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen.	\$42.13	8/10/2020	TBD
03	86409	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer.	\$105.33	8/10/2020	TBD
03	0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.	\$416.78	8/10/2020	TBD
03	0226U	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum.	\$42.28	8/10/2020	TBD
03	86413	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative.	\$42.13	9/8/2020	TBD
03	87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	\$142.63	10/6/2020	TBD
03	87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	\$142.63	10/6/2020	TBD
03	87811	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$41.38	10/6/2020	TBD
03	0240U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected	\$142.63	10/6/2020	TBD
03	0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus (RSVI), upper respiratory specimen, each pathogen reported as detected or not defletched	\$142.63	10/6/2020	TBD

тоѕ	Procedure Code	Code Description	Fee	Effective Date of Service*	End Date of Servi
30	U0002	COVID-19 Lab Test Non-CDC	\$51.33	02/04/2020	04/19/2020
30	86328	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (e.g., reagent strip): severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19))	\$45.23	04/10/2020	TBD
30	86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$42.13	04/10/2020	TBD
30	87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	\$51.33	03/13/2020*	TBD
30	U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.	\$75.00	01/01/2021	TBD
30	U0004	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.	\$75.00	01/01/2021	TBD
30	U0005	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either HCPCS code U0003 or U0004) SARS-CoV-2 CMS-2020-01-R2	\$25.00	01/01/2021	TBD
30	87426	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g. SARS-CoV, SARSCOV-2 (COVID-19])	\$45.23	06/25/2020*	TBD
30	87428	Infectious agent antigen detection by immunoassay technique, (eg., enzyme immunoassay [EIA], enzyme-linked immunosorbert assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg. SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B	\$73.49	11/10/2020	TBD
30	0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$416.78	06/25/2020*	TBD
30	0224U	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed	\$42.13	06/25/2020*	TBD
30	0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$416.78	05/20/2020*	TBD
30	86408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen.	\$42.13	8/10/2020	TBD
30	86409	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer.	\$105.33	8/10/2020	TBD
30	0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.	\$416.78	8/10/2020	TBD
30	0226U	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum.	\$42.28	8/10/2020	TBD
30	86413	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative.	\$42.13	9/8/2020	TBD
30	87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	\$142.63	10/6/2020	TBD
30	87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	\$142.63	10/6/2020	TBD
30	87811	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$41.38	10/6/2020	TBD
30	0240U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected	\$142.63	10/6/2020	TBD
30	0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus (RSVI), upper respiratory specimen, each pathogen reported as detected or not detected	\$142.63	10/6/2020	TBD

TOS	Procedure Code	Code Description	Fee	Effective Date of Service*	End Date of Service
37	U0002	COVID-19 Lab Test Non-CDC	\$51.33	02/04/2020	04/19/2020
37	86328	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19))	\$45.23	04/10/2020	TBD
37	86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$42.13	04/10/2020	TBD
37	87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	\$51.33	03/13/2020*	TBD
37	U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.	\$75.00	01/01/2021	TBD
37	U0004	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.	\$75.00	01/01/2021	TBD
37	U0005	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either HCPCS code U0003 or U0004) SARS-CoV-2 CMS-2020-01-R2	\$25.00	01/01/2021	TBD
37	87426	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g. SARS-CoV, SARSCOV-2 (COVID-19])	\$45.23	06/25/2020*	TBD
37	87428	Infectious agent antigen detection by immunoassay technique, (eg., enzyme immunoassay [EIA], enzyme-linked immunosorbert assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg. SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B	\$73.49	11/10/2020	TBD
37	0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$416.78	06/25/2020*	TBD
37	0224U	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed	\$42.13	06/25/2020*	TBD
37	0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$416.78	05/20/2020*	TBD
37	86408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen.	\$42.13	8/10/2020	TBD
37	86409	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer.	\$105.33	8/10/2020	TBD
37	0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.	\$416.78	8/10/2020	TBD
37	0226U	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum.	\$42.28	8/10/2020	TBD
37	86413	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative.	\$42.13	9/8/2020	TBD
37	87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique	\$142.63	10/6/2020	TBD
37	87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	\$142.63	10/6/2020	TBD
37	87811	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$41.38	10/6/2020	TBD
37	0240U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected	\$142.63	10/6/2020	TBD
37	0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus (RSVI), upper respiratory specimen, each pathogen reported as detected or not detected	\$142.63	10/6/2020	TBD

19 19 19 19 19 19 19 19	TOS	Procedure Code	Code Description	Fee	of Service*	End Date of Serv
98328 method (e.g., reappert strip); severe and respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus diseased (CVVID-19) 987635 methods, severe and respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus diseased (CVVID-19)) 987635 methods agent detection by ruckles acid (DNA or RNA); severe acid respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus diseases (CVVID-19)), amplified prote benchique or coronavirus 2 (SARS-CoV-2) (Coronavirus diseases (CVVID-19)), amplified prote benchique, making use of high throughput technologies as described by CNB-2020-01-R. 99	39	U0002	COVID-19 Lab Test Non-CDC	\$51.33	02/04/2020	04/19/2020
9 87635 (COVID-19)	39	86328	method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	\$45.23	04/10/2020	TBD
97 100003 100000 100000 100000 100000 100000 100000 100000 100000 100000 100000 100000 100000 1000000 1000000 1000000 1000000 10000000 10000000 100000000	39	86769		\$42.13	04/10/2020	TBD
U0003 U0003 U0004 U000	39	87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	\$51.33	03/13/2020*	TBD
U0004 Subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-11-2	39	U0003	coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique,	\$75.00	01/01/2021	TBD
100005 1	39	U0004	subtypes (includes all targets), non-CDC, making use of high throughput technologies as	\$75.00	01/01/2021	TBD
87426 [EIA], enzyme-linked immunosother assay [ELISA], immunochemiluminometric assay (IMCA) qualitative or semiquantitative, multiple-steeper method: severe acute respiratory syndrome coronavirus (e.g. SARS-COV, SARS-COV-) (COVID-19) 87428 [Article of the control of the control of the covid of the covi	39	U0005	coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either HCPCS code	\$25.00	01/01/2021	TBD
anyme-linked immunosorbent assay [IELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMA] qualitative or semigruantitative; severe acute respiratory syndrome coronavirus (eg. SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus (2 ISARS-CoV-2) (COV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus disease (COVID-19]), includes titer(s), when performed infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected (Cov-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected (Cov-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected (Cov-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected (Cov-2), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease) (COVID-19)); itter. 39 B6408 Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not de	39	87426	[EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome	\$45.23	06/25/2020*	TBD
O233U ONA or RNA), 22 largets including severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (Coronavirus disease COVID-19), includes titer(s), when performed Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 largets including severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected (ONA or RNA), 22 largets including severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (Qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected (Coronavirus disease (COVID-19)); screen. \$416.78	39	87428	enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza	\$73.49	11/10/2020	TBD
Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected (Coronavirus disease (COVID-19); screen. \$416.78	39	0223U	(DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not	\$416.78	06/25/2020*	TBD
O202U (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected O5/20/2020* O5/2020* O5/20	39	0224U		\$42.13	06/25/2020*	TBD
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)); streen. S42.13 S710/2020	39	0202U	(DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not	\$416.78	05/20/2020*	TBD
Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)): titer. Infectious disease (COVID-19): Early syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected. Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus 4 (SARS-CoV-2) (Coronavirus disease (COVID-19)). ELISA, plasma, serum. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)) and influenza virus disease (COVID-19)) and influenza virus disease (COVID-19)) and influenza virus types A and B, multiplex amplified probe technique Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)) and influenza virus types A and B, and respiratory syndrome coronavirus disease (COVID-19), influenza virus types A and B, and respiratory syndral virus, multiplex amplified probe technique Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)) influenza A; influenza B; upper acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Influenza A; influenza B), upper respiratory specimen, each pathogen reported as detected or not detected.	39	86408		\$42.13	8/10/2020	TBD
Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected. 39 0226U SARS-CoV-2) (Coronavirus disease) (COVID-19), ELISA, plasma, serum. 39 86413 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease) (COVID-19)) antibody, quantitative. 39 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease) (COVID-19)) and influenza virus types A and B, multiplex amplified probe technique 39 R7636 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease) (COVID-19), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique 19 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease) (COVID-19), influenza virus types A and B, and respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease) (COVID-19), influenza virus types A and B, and respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease) (COVID-19), influenza virus types A and B, and respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease) (COVID-19), influenza virus types A and B, and respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease) (COVID-19), influenza virus types A and B, and respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease) (COVID-19), influenza virus types A and B, and respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A, influenza B, upper saute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A, influenza B, upper saute respiratory syndrome coronavirus 2 (SARS-	39	86409	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)	\$105.33	8/10/2020	TBD
SARS-CoV-2) (Coronavirus disease (COVID-19)), ELISA, plasma, serum. S42.28 of 10/2/22	39	0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported	\$416.78	8/10/2020	TBD
19] antibody, quantitative. Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19]) Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected	39	0226U	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum.	\$42.28	8/10/2020	TBD
29 87636 coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory synorytial virus, multiplex amplified probe technique Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), (Coronavirus disease [COVID-19]) Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory specimen, each pathogen reported as detected or not detected Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory specimen, each pathogen reported as detected or not detected	39	86413		\$42.13	9/8/2020	TBD
39 87637 coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, \$142.63 10/6/2020 and respiratory syncytial virus, multiplex amplified probe technique 39 87811 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	39	87636	coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and	\$142.63	10/6/2020	TBD
39 87811 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID- \$41.38 10/6/2020 13)) Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory specimen, each pathogen reported as detected or not detected Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory specimen, each pathogen reported as detected or not detected	39	87637	coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B,	\$142.63	10/6/2020	TBD
39 0240U acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza B, influenza B), upper s142.63 10/6/2020 respiratory specimen, each pathogen reported as detected or not detected infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe	39	87811	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-	\$41.38	10/6/2020	TBD
courte reconjectors a unidrome accepta significant A (CARC Co.) (2) influence A influence B reconjectors	39	0240U	acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected	\$142.63	10/6/2020	TBD
39 0241U acute respiratory syndrome coronavirus z [SARS-CoV-2], inituenza B, respiratory syndrome coronavirus z [SARS-CoV-2]	39	0241U	acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not	\$142.63	10/6/2020	TBD

тоѕ	Procedure Code	Code Description	Fee	Effective Date of Service*	End Date of Service
40	U0002	COVID-19 Lab Test Non-CDC	\$53.04	02/04/2020	04/19/2020
40	86328	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (e.g., reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease) (COVID-19))	\$45.23	04/10/2020	TBD
40	86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$42.13	04/10/2020	TBD
40	87635	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	\$53.04	03/13/2020*	TBD
40	U0003	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.	\$75.00	01/01/2021	TBD
40	U0004	2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R.	\$75.00	01/01/2021	TBD
40	U0005	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either HCPCS code U0003 or U0004) SARS-CoV-2 CMS-2020-01-R2	\$25.00	01/01/2021	TBD
40	87426	Infectious agent antigen detection by immunoassay technique, (e.g., enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [EIJSA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (e.g. SARS-CoV, SARSCoV-2 [COVID-19])	\$46.74	06/25/2020*	TBD
40	87428	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B	\$73.49	11/10/2020	TBD
40	0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$430.66	06/25/2020*	TBD
40	0224U	Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed	\$43.53	06/25/2020*	TBD
40	0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	\$430.66	05/20/2020*	TBD
40	86408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen.	\$43.53	8/10/2020	TBD
40	86409	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer.	\$108.84	8/10/2020	TBD
40	0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.	\$430.66	8/10/2020	TBD
40	0226U	Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum.	\$43.69	8/10/2020	TBD
40	86413	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative.	\$43.53	9/8/2020	TBD
40	87636	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease (COVID-19)) and influenza virus types A and B, multiplex amplified probe technique	\$147.38	10/6/2020	TBD
40	87637	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique	\$147.38	10/6/2020	TBD
40	87811	Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])	\$42.76	10/6/2020	TBD
40	0240U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], Influenza A, Influenza B), upper respiratory specimen, each pathogen reported as detected or not detected	\$147.38	10/6/2020	TBD
40	0241U	Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected	\$147.38	10/6/2020	TBD
Revisor	effective data	of service to align with guidance from CMS			
Kevised	chective date	or so rice to align with guidance in one one			
OS (Type	of Service):	File from which claims are paid.			
.,,,,,					
03	(Nurse Practi	ysician-owned labs and independent laboratory services. itoners, Clinical Nurse Specialists, Certified Nurse Midwives, and Physician Assistants are 0% of this fee,			
30		Outpatient Hospital			
37		Outpatient Hospital			
39	State Hospitals Outpatient Hospital				
40	Sole Commu	nity Outpatient Hospital			